Atlantic Coastal Acquisition Corp. II (ACAB) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
6 ST JOHNS LANE, FLOOR 5 NEW YORK, NY 10013 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 265 | 392 | |||
| Cash and cash equivalents | 265 | 392 | |||
| Prepaid expense | 378 | ||||
| Asset, held-in-trust | 29,729 | ||||
| Other undisclosed current assets | |||||
| Total current assets: | 29,994 | 770 | |||
| Noncurrent Assets | |||||
| Asset, held-in-trust | 7,372 | 309,790 | |||
| Total noncurrent assets: | 7,372 | 309,790 | |||
| TOTAL ASSETS: | 37,366 | 310,561 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 469 | 1,243 | |||
| Accrued liabilities | 469 | 1,243 | |||
| Other undisclosed accounts payable and accrued liabilities | |||||
| Financial instruments subject to mandatory redemption, settlement terms, share value, amount | 29,729 | ||||
| Other liabilities | |||||
| Other undisclosed current liabilities | 5,190 | 899 | |||
| Total current liabilities: | 35,388 | 2,142 | |||
| Noncurrent Liabilities | |||||
| Liabilities, other than long-term debt | 10,500 | 10,500 | |||
| Deferred compensation liability, classified | 10,500 | 10,500 | |||
| Other undisclosed noncurrent liabilities | 0 | ||||
| Total noncurrent liabilities: | 10,500 | 10,500 | |||
| Total liabilities: | 45,888 | 12,642 | |||
| Temporary equity, carrying amount | 7,293 | 309,098 | |||
| Equity | |||||
| Equity, attributable to parent, including: | (15,815) | (11,179) | |||
| Accumulated deficit | (15,816) | (11,180) | |||
| Other undisclosed equity, attributable to parent | 1 | 1 | |||
| Other undisclosed equity | (0) | ||||
| Total equity: | (15,815) | (11,179) | |||
| TOTAL LIABILITIES AND EQUITY: | 37,366 | 310,561 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Revenues (Net Investment Income) | ||||
| Gross profit: | ||||
| Operating expenses | ||||
| Other undisclosed operating loss | (1,666) | (2,050) | ||
| Operating loss: | (1,666) | (2,050) | ||
| Nonoperating income | 5,665 | 3,761 | ||
| Income (loss) from continuing operations before income taxes: | 3,999 | 1,711 | ||
| Income tax expense | (1,177) | (824) | ||
| Net income (loss) attributable to parent: | 2,821 | 887 | ||
| Preferred stock dividends and other adjustments | 29,729 | |||
| Other undisclosed net income available to common stockholders, basic | ||||
| Net income available to common stockholders, diluted: | 32,550 | 887 | ||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|
| Net income (loss): | 2,821 | 887 | ||
| Comprehensive income (loss), net of tax, attributable to parent: | 2,821 | 887 | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.